This could be explained by the finding that B/I preferentially activate CD62Llow CD8+ T cells, which are enriched in tumor antigen-specificity, compared to their naive CD62LHigh counterparts in lymph nodes harvested from mice with tumors (23). The gene discussed is CD8A; the disease is neoplasm.